BioSpace News Archive

FX received 510k clearances for their TiN (Titanium Nitride) Coated Humeral Heads and Glenospheres. The new addition of TiN coated humeral heads and glenospheres adds unique-to-market prostheses to the FX portfolio.

Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or fo

Dyne Therapeutics , a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced the appointment of pediatric neurologist Francesco Muntoni, FRCPCH, FMedSci, to its Scientific Advisory Board. Dr. Muntoni is a global leader in clinical research into neuromuscular disease, with particular expertise in clinical care, clinical trial design and drug development for Duchenne

JW Therapeutics , a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS ® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries. This press rel

IQVIA™ (NYSE: IQV) today announced it is joining forces with JDRF , the leading global organization funding type 1 diabetes (T1D) research, to use non-identified patient-level, real world data and analytics to address unmet n

Possible Phase 3 Would Increase Total Project Revenue to $6.7 million

Notch Therapeutics Inc., a biotechnology company creating universally compatible, off-the-shelf T cell therapies for cancer and immune disorders from renewable stem cell sources, is pleased to announce the appointment of David Main as President and Chief Executive Officer. Notch is applying its scalable Engineered Thymic Niche (ETN) te

Agreement makes the DarioHealth RPM solution available to chronic care patients at general practices across the UK and Ireland Further advances DarioHealth’s international growth strategy and ongoing transition to a global SaaS-based digital therapeutics leader

SIA, a privately-held medical device manufacturer, today announced the appointment of Jason O’Hearn as Chief Commercial Officer.

Kronos Bio, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription, today announced the appointment of Barbara Kosacz as Chief Operating Officer and General Counsel. Ms. Kosacz joins the Company with more than 25 years of experience providing strategic